A subgroup of schizophrenia patients with motor disorders identified

January 29, 2014

Researchers led by Marta Barrachina, Institute of Neuropathology of the Bellvitge Biomedical Research Institute (IDIBELL) have identified a new subgroup of patients suffering from schizophrenia characterized by motor disorders.

The results of the study, which was conducted in collaboration with the research team Mairena Martin at the University of Castilla La Mancha at Ciudad Real and clinical researchers of the Health Park Sant Joan de Deu at Sant Boi de Llobregat, have been published in the online edition of the Journal of Psychiatric Research and was funded by the TV3 Marathon in the 2008 edition.

Schizophrenia is a serious mental illness. From a clinical point of view is considered grouping several diseases that are not well defined or characterized by biomarkers.

Barrachina team studies the A2A adenosine receptor, which is highly expressed in the at the central nervous system and is involved in the control of movement. Furthermore this protein inhibits the activity of dopamine D2 receptor, hyperactivated in and typical antipsychotics target.

"We studied the post- mortem brains of ," explains Barrachina "and we found that 50% had very low levels of adenosine A2A receptor. Interestingly, when comparing these data with clinical information provided by the clinical investigators of the study, we note that these patients had motor disorders." "In addition, we identified an epigenetic mechanism associated with the decreased receptor expression."

According to the researcher, this finding allows to "identify a new subset of schizophrenia patients with motor disorders."

This study opens the door to a clinical trial, based on radioimage, which would detect the levels of this protein and identify these patients and also to confirm the results obtained in the postmortem brains of patients. Barrachina team proposes to apply a specific combination therapy of antipsychotics and agonists of A2A adenosine. "Thus, the activity of adenosine A2A receptor will be favoured, reducing the dose of antipsychotics."

Explore further: Research sheds new light on heroin addiction

More information: Villar-Menéndez I, Díaz-Sánchez S, Blanch M, Albasanz JL, Pereira-Veiga T, Monje A, Planchat LM, Ferrer I, Martín M and Barrachina M. Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia. Journal of Psychiatric Research (2014),

Related:

Aliagas E, Villar-Menéndez I, Sévigny J, Roca M, Romeu M, Ferrer I, Martín-Satué M, Barrachina M. Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the "adenosine hypothesis". Purinergic Signal. 2013 Dec;9(4):599-608. DOI: 10.1007/s11302-013-9370-7. Epub 2013 Jun 16. PubMed. PMID: 23771238.

Villar-Menéndez I, Blanch M, Tyebji S, Pereira-Veiga T, Albasanz JL, Martín M, Ferrer I, Pérez-Navarro E, Barrachina M. Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease. Neuromolecular Med. 2013 Jun;15(2):295-309. DOI: 10.1007/s12017-013-8219-0. Epub 2013 Feb 6. PubMed PMID: 23385980.

Related Stories

Research sheds new light on heroin addiction

May 14, 2008

Researchers from the Howard Florey Institute in Melbourne have identified a factor that may contribute towards the development of heroin addiction by manipulating the adenosine A2A receptor, which plays a major role in the ...

Receptor may hold key to multiple sclerosis treatment

June 11, 2012

(Medical Xpress) -- A receptor recently discovered to control the movement of immune cells across central nervous system barriers (including the blood-brain barrier) may hold the key to treating multiple sclerosis (MS), a ...

Scientists achieve highest resolution ever for human protein

July 12, 2012

Never has a crystal structure of a human protein molecule in a cell wall been so crystal clear. Leiden researchers Ad IJzerman and Laura Heitman, together with American colleagues, have achieved the most detailed crystal ...

Jumping DNA in the brain may be a cause of schizophrenia

January 2, 2014

Stretches of DNA called retrotransposons, often dubbed "junk DNA", might play an important role in schizophrenia. In a study published today in the journal Neuron, a Japanese team revealed that LINE-1 retrotransposons are ...

New target explored for psychiatric drug development

January 29, 2014

(Medical Xpress)—In a surprising discovery, neuroscientists have found that a breakdown product of cholesterol in the brain may be a target for developing new drugs to treat schizophrenia and other mental illnesses.

Recommended for you

Sleep makes relearning faster and longer-lasting

August 22, 2016

Getting some sleep in between study sessions may make it easier to recall what you studied and relearn what you've forgotten, even 6 months later, according to new findings from Psychological Science, a journal of the Association ...

Psychosis associated with low levels of physical activity

August 25, 2016

A large international study of more than 200,000 people in nearly 50 countries has revealed that people with psychosis engage in low levels of physical activity, and men with psychosis are over two times more likely to miss ...

Have we misunderstood post-traumatic stress disorder?

August 22, 2016

In understanding war-related post-traumatic stress disorder, a person's cultural and professional context is just as important as how they cope with witnessing wartime events, which could change the way mental health experts ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.